LR—850型和OMRONHEM—732C型电子血压计的准确性评价

目的 评价LR－850多功能全自动电子血压计和OMRONHEM－732C型电子血压计的准确性。方法 根据英国高血压协会（BHS）及医学仪器进展协会（AAMI）的规定,对两种电子血压计进行了听诊法及电子血压计同步测定的对比研究。结果 LR－850多功能全自动电子血压计所测收缩压值达到BHS的A级标准,而OMRON HEM－732C电子血压计所测收缩压值达到BHS的C级标准,两种血压计舒张压值均达到BHS的A级标准,且都通过了AAMI的规定要求。结论 LR－850型多功能全自动电子血压计和OMRONHEM－732C电子血压计均具有良好的准确性,可用于家庭及医院内的血压监测。     

LR-850型和OMRON HEM-732C型电子血压计的准确性评价

目的评价LR-850多功能全自动电子血压计和OMRONHEM-732C型电子血压计的准确性。方法根据英国高血压协会（BHS）及医学仪器进展协会（AAMI）的规定，对两种电子血压计进行了听诊法及电子血压计同步测定的对比研究。结果LR-850多功能全自动电子血压计所测收缩压值达到BHS的A级标准，而OMRONHEM-732C电子血压计所测收缩压值达到BHS的C级标准，两种血压计舒张压值均达到BHS的A级标准，且都通过了AAMI的规定要求。结论LR-850型多功能全自动电子血压计和OMRONHEM-732C电子血压计均具有良好的准确性，可用于家庭及医院内的血压监测。     

电子血压计与汞柱血压计测量结果对比观察

<正>血压测量是临床工作中一项重要的操作,可以协助诊断疾病以及评价用药效果。近年来,电子血压计广泛应用于临床,其性能不断提升。本院在临床上发现袖带式电子血压计对年龄较大或是臂围较细的患者进行血压测量时,其测量结果较汞柱血压计的测量值有不同程度的差异。本文通过对比两种血压计的测量结果以观察电子血压计在血压测量中的准确性。1资料与方法1.1一般资料:选取2014年3月至5月我院住院患     

怎样判断电子血压计的准确性

最新的《中国高血压防治指南》指出,家庭血压监测首先要选择合适的血压监测设备．并进行血压测量知识与技能培训。虽然水银柱血压计测量血压更为准确可靠．但是测量方法相对复杂,不适合普通人作为日常血压监测设备。因此电子血压计就成了家庭监测血压的重要工具。     

宽袖带与常规宽度袖带臂式电子血压计测量血压结果的对比分析

目的 探索宽袖带(宽度为18 cm)与常规宽度袖带(宽度为13 cm)臂式电子血压计在测量血压值的差异.方法 选择2018年5-11月于河北医科大学第二医院心内科住院患者1 155例,其中男性占47％,年龄(59.7±13.2)岁.根据臂围大小将患者分为4组:第1组臂围范围为15～21 cm,第2组为22～26 cm,...     

欧姆龙HEM-711型便携式电子血压计的准确性

评价欧姆龙ＨＥＭ－７１１型便携式电子血压计的准确性。方法根据英国高血压协会（ＢＨＳ）以及医学仪器进展协会（ＡＡＭＩ）的规定,对１２６例进行了听诊法及电子血压测定的对比研究。结果欧姆龙ＨＥＭ－７１１型便携式血压计收缩压和舒张压均达到了ＢＨＳ的Ａ级标准,并通过了ＡＡＭＩ的规定要求。两种方法间呈线形相关,其回归方程为收缩压ＳＢＰ：＾ｙ＝１．０９＋０．９６０ｘ（ｒ＝０．９７６）;ＤＢＰ：＾ｙ＝５．３＋０．９７０ｘ（ｒ＝０．９１６）。结论欧姆龙ＨＥＭ－７１１型便携式血压计具有良好的准确性,可用于家庭及医院内的血压监测。     

欧姆龙HEM—711型例携式电子血压计的准确性

目的 评价欧姆龙ＨＥＭ－７１１型便携式电子血压计的准确性。方法 根据英国高血压协会（ＢＨＳ）以及医学仪器进展协会（ＡＡＭＩ）的规定，对１２６例进行了听诊法及电子血压测定的对比研究。结果 欧姆龙ＨＥＭ－７１１型便携式血压计收缩压和舒张压均达到了ＢＨＳ的Ａ级标准，并通过了ＡＡＭＩ的规定要求。两种方法间呈线形相关，其加归方程为收缩压ＳＢＰ：ｙ＝１．０９＋０．９６０ｘ（ｒ＝０．９７６）；ＤＢＰ：ｙ＝５．３     

电子血压计与台式水银血压计测量儿童青少年血压的比对研究

目的比较分析电子血压计(示波法)与台式水银血压计(听诊法)对儿童青少年血压的测量结果,对电子血压计测量儿童青少年血压的准确性进行评价。方法 2010年分层整群抽取北京市城、郊3～17岁儿童青少年,各年龄组至少100人,男女各半。问卷调查生活行为信息,测量身高、体质量、腰围,使用电子血压计(欧姆龙HEM-759P)与台式水银血压计分别测量血压两次,交替进行,记录血压及脉搏。比较两法测量结果,Bland-Altman法比较两法测量一致性。结果总计1695名3～17岁儿童青少年参加调查,各年龄组人数基本相同,男女比例0.99。各年龄组电子血压计与台式水银血压计测量结果互有高低,电子血压计测量值高于台式水银血压计居多。两法测量收缩压差值绝对值≤5,≤10和≤15mm Hg所占比例分别为54.2%,82.9%和100%;以台式水银血压计Korotcoff第Ⅳ音(K4)评价舒张压时,两法测量舒张压差值绝对值≤5,≤10和≤15mmHg所占比例分别为42.3%,70.4%和87.2%,以台式水银血压计Korotcoff第Ⅴ音(K5)评价舒张压时,3组比例分别为46.1%,70.6%和84.8%。调整性别、年龄,两法测量收缩压间、电子血压计舒张压与台式水银血压计K4间、电子血压计舒张压与台式水银血压计K5间的偏相关系数分别为0.716、0.448和0.353(P<0.01)。Bland-Altman分析显示两法收缩压差值95%一致性界限为-13.5～19.6mmHg,电子血压计舒张压与台式水银血压计K4差值95%一致性界限为-22.5～15.1mm Hg,电子血压计舒张压与台式水银血压计K5差值95%一致性界限为-20.3～28.4mm Hg。结论电子血压计测量结果高于台式水银血压计,测量结果比较稳定,两方法测量结果一致性好,电子血压计可用于儿童青少年人群血压的现场调查。     

电子血压计测量血压的重复性研究

目的:在一般人群中评价电子血压计测量血压的重复性.方法:选择492例研究对象,所有研究对象在标准状态下采用电子血压计测量血压3次,取3次测量值均数作为平均血压水平,采用重复测量资料的方差检验分析3次测量值之间差异有无统计学意义,同时根据年龄和脉压分层分析可能影响电子血压计测量血压重复性的影响因素.结果:收缩压、舒张压、平均动脉压和脉压的3次测量值间两两比较差异均有统计学意义,第1次测量值最高,第2次和第3次测量值依次降低.根据年龄分组后,在不同年龄组中的3次测量值仍是第1次最高,第2次和第3次测量值依次降低,差异有统计学意义.根据脉压分组后,在脉压<35 mmHg组,收缩压、舒张压、平均动脉压和脉压在3次测量间差异均无统计学意义.在脉压≥35 mmHg(1 mmHg=0.133 kPa)组,无论收缩压、舒张压还是平均动脉压,3次测量值间两两比较差异均有统计学意义,测量值随着测量次数逐渐降低.结论:电子血压计3次测量间两两比较的差异均有统计学意义,而脉压可能是影响电子血压计测量血压重复性的因素之一.     

电子血压计可靠不可靠？

本刊从2005年第1期起开辟“焦点大家谈”专栏，目的是对临床医生、病人都关心的、常见的、有争论的焦点问题，请广大临床医生根据自己的实践畅述己见，让更多的人参加讨论。欢迎提出问题，欢迎投稿参加讨论。2005年前半年将要讨论的题目，请参见高血压杂志，2004，12(6)：555     

HEM-6000手腕式血压计的可靠性

目的 采用美国医疗器械检测协会(AAMI)标准,对HEM-6000手腕式血压计的血压测量精确度进行临床验证研究.方法 入选对象为18岁以上成年人,共91人.腕部测压结果与听诊法比较.每位受试者用2种方法同时各进行3次坐位血压测量,对91人的273对血压测量值用以下2种方法进行统计分析:(1)先计算出2种测压方法得到的血压测量值误差,再求得误差的平均值和标准偏差.(2)先计算出每位受试者用2种测压方法得到的血压平均值的差值,再求得该差值的平均值和标准偏差.结果 根据方法1得到的收缩压(SBP)和舒张压(DBP)的测量误差分别为(0.5±7.1)mm Hg和(-1.6±6.1)mm Hg;根据方法2得到的结果分别(0.5±6.1)mm Hg和(-1.6±5.3)mm Hg.血压值的水平及手腕周长对测量误差无影响.结论 HEM-6000手腕式血压计通过AAMI检验标准,可推荐患者用于家庭自我测压.     

HEM-6000手腕式血压计的可靠性

目的采用美国医疗器械检测协会(AAMI)标准,对HEM-6000手腕式血压计的血压测量精确度进行临床验证研究。方法入选对象为18岁以上成年人,共91人。腕部测压结果与听诊法比较。每位受试者用2种方法同时各进行3次坐位血压测量,对91人的273对血压测量值用以下2种方法进行统计分析:(1)先计算出2种测压方法得到的血压测量值误差,再求得误差的平均值和标准偏差。(2)先计算出每位受试者用2种测压方法得到的血压平均值的差值,再求得该差值的平均值和标准偏差。结果根据方法1得到的收缩压(SBP)和舒张压(DBP)的测量误差分别为(0.5±7.1)mm Hg和(-1.6±6.1)mm Hg;根据方法2得到的结果分别(0.5±6.1)mm Hg和(-1.6±5.3)mm Hg。血压值的水平及手腕周长对测量误差无影响。结论HEM-6000手腕式血压计通过AAMI检验标准,可推荐患者用于家庭自我测压。     

Validation of the Omron HEM-907 device for blood pressure measurement

BACKGROUND: The aim of this study was to validate the Omron HEM-907 blood pressure (BP) measuring device according to the international validation protocol. DESIGN: The international validation protocol is divided into two phases: the first phase is performed on 15 selected subjects and if the device passes this phase, 18 more subjects are selected making a total number of 33 subjects on which the final validation is performed. METHODS: For each subject, BP measurements were performed simultaneously by two trained observers using mercury sphygmomanometers alternately with the Omron HEM-907 device. In all, 99 measurements were obtained for comparison. The difference between the BP value given by the device and that obtained by the two observers (mean of the two observers) was calculated for each measure. RESULTS: The difference between the two observers was -1 +/- 2 mmHg for the systolic BP (SBP) and for the diastolic BP (DBP). The Omron HEM-907 passed the first phase of the validation process. For the second phase, the average differences between the device and mercury sphygmomanometer readings were -1 +/- 7 and -5 +/- 6 mmHg for SBP and DBP respectively. Readings for the HEM-907 device differed by less than 5 mmHg for 61 of the systolic readings and 52 of the diastolic readings; by less than 10 mmHg for 85 of the systolic readings and 85 of the diastolic readings; and by less than 15 mmHg for 94 of the systolic readings and 96 of the diastolic readings. CONCLUSIONS: The Omron HEM-907 device passes the two phases of the international validation protocol.     

Evaluation of the overall efficacy of the Omron office digital blood pressure HEM-907 monitor in adults.

BACKGROUND: Non-invasive self blood pressure monitoring has become increasingly popular. To assure the accuracy of devices used for this purpose, all need to be validated independently prior to marketing. The objective of this study was to assess the accuracy of the HEM-907, a new semi-automatic, non-invasive, oscillometric blood pressure monitoring device specifically designed to be used in the clinic or physician's office setting. METHODS: Blood pressure measurements taken employing this device were compared with the results obtained by two experienced observers using a mercury sphygmomanometer on 100 subjects and patients (384 measurements). The limits of agreement were calculated for the device compared with the results of the two observers according to the standards of the Association for the Advancement of Medical Instrumentation (AAMI). RESULTS: The agreement between the two observers was -0.36+/-2.32mmHg for systolic blood pressure and 0.02+/-2.42mmHg for diastolic blood pressure. The agreement between the device and the observers was 1.56+/-4.42mmHg and 3.49+/-4.61mmHg for systolic and diastolic blood pressure respectively. CONCLUSIONS: The Omron HEM-907 satisfied the AAMI criteria for accuracy for a non-invasive blood pressure monitoring device.     

Validation of the Omron 705IT (HEM-759-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol

BACKGROUND: The Omron 705IT (HEM-759-E, Omron Corporation, Kyoto, Japan) is an automated oscillometric upper arm blood pressure monitor for the professional and home use markets. The aim of this study was to validate the accuracy of this device according to the British Hypertension Society and the Association for the Advancement of Medical Instrumentation SP10 validation criteria. METHODS: Study participants were recruited until a total of 85 were obtained that filled the blood pressure categories specified by the British Hypertension Society protocol. Recruitment to the study was from the general medical and specialist clinics and from the staff at Guy's & St Thomas' Hospital in London, UK. Nine sequential same-arm blood pressure readings were taken from each participant by two trained observers, alternating between mercury reference sphygmomanometers and the Omron 705IT (HEM-759-E). The differences between the reference and test device readings, for both systolic and diastolic pressures, were compared with British Hypertension Society and Association for the Advancement of Medical Instrumentation criteria to determine the outcome of the study. RESULTS: The Omron 705IT (HEM-759-E) is graded 'A' for systolic and 'A' for diastolic blood pressures according to the British Hypertension Society criteria. The mean (standard deviation) of the difference between the observer and the device measurements was 0.60 (6.0) mmHg for systolic and -3.15 (6.6) mmHg for diastolic pressures, respectively. The device, therefore, also satisfies the Association for the Advancement of Medical Instrumentation SP10 standard, that requires differences of less than +/-5 (8) mmHg. CONCLUSIONS: The Omron 705IT (HEM-759-E) achieved an 'A/A' performance classification under the British Hypertension Society criteria and passes the Association for the Advancement of Medical Instrumentation requirements for the study population. It can be recommended for professional and home-use in an adult population.     

Evaluation of the efficacy of the Omron HEM-737 IntelliSense device for use on adults according to the recommendations of the Association for the Advancement of Medical Instrumentation

BACKGROUND: Automatic noninvasive blood pressure measuring devices should be independently validated prior to marketing by using standard guidelines such as those published by the Association for the Advancement of Medical Instrumentation and British Hypertension Society. OBJECTIVE: To assess a new noninvasive oscillometric automatic home blood pressure (Omron HEM-737 IntelliSense; Omron Healthcare Inc., Vernon Hills, Illinois, USA). METHODS: We compared the device's measurements with mercury column measurements for 90 subjects (270 measurements). In addition to calculation of the limits of agreement for the device versus observers, we also dtermined the impacts of age, level of blood pressure, body mass, and arm size on the levels of agreement. RESULTS: Observers showed that close agreement was attained, with mean differences of 0.42 +/- 3.65 mmHg for systolic blood pressure and 0.37 +/- 3.59 mmHg for diastolic blood pressure. The proportions of values agreeing to within 5, 10, and 15 mmHg were 88, 99, and 100% for systolic and 86, 100, and 100% for diastolic blood pressure for the two obsevers. The observer-device disagreement was 0.76 +/- 6.55 mmHg for systolic and 1.0 +/- 5.5 mmHg for diastolic blood pressure. The proportions of values agreeing to within 5, 10, and 15 mmHg were 71, 93, and 97% for systolic and 77, 96, and 98% for diastolic blood pressure for the observers and device. CONCLUSIONS: The Omron HEM-737 IntelliSense satisfied the Association for the Advancement of Medical Instrumentation's criteria for a general adult population across large ranges of age, blood pressure, body mass, and arm circumference. These findings support the use of this recorder for out-of-office self-monitoring of blood pressure.     

Validation of the Omron M7 (HEM-780-E) oscillometric blood pressure monitoring device according to the British Hypertension Society protocol

BACKGROUND: The Omron M7 (HEM-780-E) is an automated oscillometric upper arm blood pressure monitor for the professional and home use markets. The aim of this study was to validate the accuracy of this device according to the British Hypertension Society (BHS) and the Association for the Advancement of Medical Instrumentation (AAMI) SP10 validation criteria. METHODS: Participants were recruited until a total of 85 were obtained that filled the blood pressure ranges specified by the BHS protocol. Recruitment to the study was from the general medical and specialist clinics and from the staff at Guy's and St Thomas' Hospital in London, UK. Nine sequential same-arm blood pressure readings were taken from each participant by two trained observers, alternating between a mercury reference sphygmomanometer and the Omron M7 (HEM-780-E). The differences between the reference and test device readings, for both systolic and diastolic pressures, were compared with BHS and AAMI criteria to determine the outcome of the study. RESULTS: The Omron M7 (HEM-780-E) is graded 'A' for systolic and 'A' for diastolic blood pressures according to the BHS criteria. The mean (standard deviation) of the difference between the observer and the device measurements was 0.75+/-6.5) mmHg for systolic and 1.33+/-5 mmHg for diastolic pressures. The device, therefore, also satisfies the AAMI SP10 standard for the study population, which requires differences of <+/-5 (8) mmHg. CONCLUSION: The Omron M7 (HEM-780-E) achieved an 'A/A' performance classification under the BHS criteria and passed the AAMI requirements for the study population. It can be recommended for professional and home-use in this population.     

Validation of the Omron M6 (HEM-7001-E) upper arm blood pressure measuring device according to the International Protocol in elderly patients

OBJECTIVE: Despite the widespread use of automated self-measurement monitors, there is limited published evidence on their accuracy and reliability on different patient groups. The objective of this study was to evaluate the accuracy and reliability of the Omron M6 (HEM-7001-E) upper-arm blood pressure (BP) device against mercury sphygmomanometer on elderly patients according to the criteria of the International Protocol. DESIGNS AND METHODS: Thirty-three patients above 65 years of age, who were classified based on the BP categories of the International Protocol, were recruited for the study. BP measurements at the upper arm with the Omron M6 were compared with the results obtained by two trained observers using a mercury sphygmomanometer. Nine sequential BP measurements were taken. During the validation study, 99 measurements were obtained from 33 patients for comparison. The first phase was carried out on 15 patients and if the device passed this phase, 18 more patients were selected. RESULTS: Mean discrepancies and standard deviations of the device sphygmomanometer were 1.4+/-5.3 mmHg for systolic BP (SBP) and -1.4+/-4.5 mmHg for diastolic BP (DBP) in the study group. The device passed phase 1 in 15 patients. In phase 2.1, from the total 99 comparisons, 76, 92, and 97 for SBP and 77, 94, and 99 for DBP were less than 5, 10, and 15 mmHg, respectively. The Omron M6 passed phases 2.1 and 2.2 in the elderly group of patients. CONCLUSION: The Omron M6 (HEM-7001-E) upper-arm BP monitor passed according to the International Protocol criteria and can be recommended for use in elderly patients.     

动态血压监测在评价慢性肾脏病合并高血压患者血压达标中的价值

目的 比较动态血压及诊室血压评价慢性肾脏病（CKD）合并高血压患者血压达标率的差异。方法 选取2012年5月～2013年2月在中南大学湘雅三医院就诊的225例慢性肾脏病合并高血压患者。收集并分析研究对象的人口学、实验室检查及血压资料。结果 （1） 诊室血压监测和动态血压监测均随着肾功能恶化,血压达标率下降。其中诊室收缩压达标率CKD5期较CKD1～2期下降有统计学意义（18.3%比36.6%,P<0.05）,动态血压监测平均血压、日间收缩压、夜间血压达标率CKD5期较CKD1～2期下降均有统计学意义（P<0.05）。（2） CKD1～2期患者动态血压高血压检出率高于诊室血压高血压检出率（79.6%比61.3%,P0.038）,而CKD5期患者动态血压高血压检出率低于诊室血压高血压检出率（83.5%比93.0%,P0.029）。结论 （1） 随着肾功能恶化,CKD合并高血压患者血压达标率逐渐降低;（2）仅使用诊室血压评价CKD患者血压是否达标及昼夜血压达标情况存在不当,推荐CKD合并高血压患者使用动态血压监测。